Onset and underpinnings of white matter atrophy at the very early state of multiple sclerosis - A two-year longitudinal MRI/MRSI study of corpus callosum

Multiple Sclerosis

Volumn 13, Issue 1, 2007, Pages 41-51

  Audoin, B ^a,b   Ibarrola, D ^a   Malikova, I ^a,b   Soulier, E ^a   Confort Gouny, S ^a   Au Duong, M V ^a   Reuter, F ^a,b   Viout, P ^a   Ali Cherif A ^b   Cozzone, P J ^a   Pelletier, J ^a,b   Ranjeva, Jean Philippe ^a  

^a CNRS   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Atrophy; CIS; Longitudinal study; MRSI; Multiple sclerosis; White matter

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS CALLOSUM; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; WHITE MATTER;

ADULT; AGE OF ONSET; ATROPHY; CORPUS CALLOSUM; DISABILITY EVALUATION; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED;

EID: 33846543897     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506071215     Document Type: Article

References (37)

1. Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387-91.
2. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-19.
3. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20.
4. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-704.
5. Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Rashid W et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005; 64: 1001-1007.
6. Ranjeva JP, Pelletier J, Confort-Gouny S, Ibarrola D, Audoin B, Le Fur Y et al. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2003; 9: 554-65.
7. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 5O: 121-27.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
9. von Kienlin M, Ziegler A, Le Fur Y, Rubin C, Decorps M, Remy C. 2D-spatial/2D-spectral spectroscopic imaging of intracerebral gliomas in rat brain. Magn Reson Med 2000; 43: 211-19.
10. Matson GB. An integrated program for amplitude-modulated RF pulse generation and re-mapping with shaped gradients. Magn Reson Imaging 1994; 12: 1205-25.
11. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 1999; 41: 649-56.
12. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-11.
13. Pelletier J, Habib M, Lyon-Caen O, Salamon G, Poncet M, Khalil R. Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis. Arch Neurol 1993; 50: 1077-82.
14. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43.
15. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003; 9: 21-27.
16. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-62.
17. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59: 1572-76.
18. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000; 214: 665-70.
19. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 2000; 174: 85-91.
20. Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. A monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004; 251: 432-39.
21. Traboulsee A, Dehmeshki J, Brex PA, Dalton CM, Chard D, Barker GJ et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002; 59: 126-28.
22. Ge Y, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001; 220: 606-10.
23. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-107.
24. Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol 2001; 58: 115-21.
25. Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 1999; 53: 1091-97.
26. Brex PA, Gomez-Anson B, Parker GJ, Molyneux PD, Miszkiel KA, Barker GJ et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999; 166: 16-22.
27. Fernando KT, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004; 127: 1361-69.
28. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999; 122: 1933-39.
29. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
30. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31: 235-41.
31. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248: 979-86.
32. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 1996; 58: 1929-35.
33. Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res Brain Res Rev 2004; 44: 83-102.
34. Brenner RE, Munro PM, Williams SC, Bell JD, Barker GJ, Hawkins CP et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993; 29: 737-45.
35. Adams CW, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92: 291-306.
36. Oh J, Henry RG, Genain C, Nelson SJ, Pelletier D. Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging. J Neurol Neurosurg Psychiatry 2004; 75: 1281-86.
37. Oh J, Pelletier D, Nelson SJ. Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch Neurol 2004; 61: 1081-86.